Radiomics Signature on Computed Tomography Imaging: Association With Lymph Node Metastasis in Patients With Gastric Cancer
Conclusions: The newly developed radiomic signature was a powerful predictor of LN metastasis and the radiomics nomogram could facilitate the preoperative individualized prediction of LN status. Introduction Gastric cancer (GC) is one of the most common malignant tumors and the second leading cause of cancer-related deaths worldwide (1). Accurate evaluation of lymph node metastasis (LNM) status in GC patients is vital for prognosis and treatment decisions (2–4). Some histopathologic factors and biomarkers (e.g., lymphatic invasion, matrix metalloproteinase-2) are found to be able to predict LNM in GC, but most of them are only available after surgery (5–9). Preoperative evaluation of LNM could provide meaningful messages for determining the options of adjuvant therapy and the adequacy of surgical resection, hence assisting in pretreatment decision making (2–4). D2 gastrectomy was accepted as the standard surgery, especially advanced GC (10). Recently, surgeons think of endoscopic resection as the best choice for early GC without LNM, on account of more postoperative complication and mortality of D2 gastrectomy (4). Besides, clinical node staging is often under estimating the higher node staging seen by pathology (3, 4). Therefore, accurate preoperative predictions of LNM status are vital for GC patients, especially at the early stage. Recent studies showed that several serum markers (e.g., serum human apurinic/apyrimidinic endonuclease 1, circulating...
Publication date: Available online 3 July 2020Source: Journal of Visceral SurgeryAuthor(s): S. Ji, X. Xu, X. Yu
Publication date: Available online 4 July 2020Source: European Journal of Surgical OncologyAuthor(s): José Daniel Subiela, Angelo Territo, Asier Mercadé, Josep Balañà, Julia Aumatell, Julio Calderon, Andrea Gallioli, Daniel A. González-Padilla, Josep Maria Gaya, Joan Palou, Alberto Breda
Publication date: Available online 3 July 2020Source: Respiratory InvestigationAuthor(s): Takahiro Takazono, Yoshifumi Imamura, Kaoru Kawakami, Naoya Yamasaki, Hiroyoshi Shimizu, Katsuhiro Usuki, Maiko Kiyohara, Tatsuro Hirayama, Masato Tashiro, Naoki Hosogaya, Tomomi Saijo, Kazuko Yamamoto, Taiga Miyazaki, Katsunori Yanagihara, Koichi Izumikawa, Hiroshi Mukae
Publication date: Available online 3 July 2020Source: European Journal of RadiologyAuthor(s): Dorothy Ibifuro Makanjuola, Abdulmohsen Alkushi, Khalid Al Anazi
Publication date: Available online 4 July 2020Source: Academic RadiologyAuthor(s): Rangarajan Purushothaman, Vibhor Wadhwa, George Koshy Vilanilam, Deshauna Rena Tucker, Linda A. Deloney, Kedar Jambhekar, Roopa Ram, Paul Spencer Lewis
Conclusion: When performing MEA, it is important to perform detailed examinations and careful monitoring of post-operative progress bearing in mind potential malignant uterine diseases. PMID: 32619375 [PubMed - as supplied by publisher]
Conclusions: The nomogram models can be useful in determining the risk of OS and RFS in elderly patients with EHCC after MWA, which can guide individual patient management.Key pointsMWA is an effective and feasible treatment for elderly patients with EHCC and can improve survival outcomes.A calibrated and objective nomogram model for the prediction of survival outcomes in elderly patients (>65 years old) may guide patient selection and MWA treatment.Older age was not deemed to be a risk factor for survival outcomes when the elderly patients with EHCC underwent MWA. PMID: 32619374 [PubMed - as supplied by publisher]
Conclusions: We demonstrated a workflow for HIFU treatment of the porcine pancreas in-vivo under MRI-guidance. This development bears significance for the development of MR-guided HIFU interventions on the pancreas as the pig is the preferred animal model for the translation of pre-clinical research into clinical application. PMID: 32619373 [PubMed - as supplied by publisher]
Authors: Li Y, Wang D, Li X Abstract Lung cancer has attracted a lot of attention because of its high morbidity and mortality. The emergence of RFA provides a new treatment for unresectable NSCLC patients. In addition to killing in situ lung tumors, RFA also provides new immuno-activated antigens, for the treatment of lung cancer. It changes the tumor microenvironment and activates the entire immune system of patients. The peripheral blood cell count is easy to achieve and the blood cells are important in tumor immunity, which changes after RFA. On the one hand, the changes in blood cells identify the immune change...
Conclusion: CBCT-guided RFA of lung tumors is a relatively safe procedure with acceptable morbidity. PMID: 32619365 [PubMed - as supplied by publisher]
More News: Academia | Adenocarcinoma | Australia Health | Biomedical Engineering | Brain | Breast Cancer | Breast Carcinoma | Canada Health | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | China Health | Clinical Trials | Colon Cancer | Colorectal Cancer | CT Scan | Epidemiology | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Germany Health | Grants | Hepatocellular Carcinoma | HER2 | Herceptin | Japan Health | John Hopkins University | Laboratory Medicine | Laparoscopy | Liver | Liver Cancer | Liver Disease | Lung Cancer | Medical Ethics | Melanoma | Nanotechnology | Nasopharyngeal Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Netherlands Health | Neurology | Neuroscience | Neurosurgery | Non-Small Cell Lung Cancer | Pathology | PET Scan | Pharmaceuticals | Radiography | Radiology | Reproduction Medicine | Science | Skin Cancer | Statistics | Study | Surgery | Training | Universities & Medical Training | Urology & Nephrology | USA Health